<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2017</study_start_year><data_sharing_plan>IPD Sharing (as of September 2022): No</data_sharing_plan><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2249799</full_dataset_link><location>United States</location><study_start_month>10</study_start_month><keyword>Trifluridine</keyword><repository>ECRIN MDR</repository><study_status>Recruiting</study_status></additional><is_claimable>false</is_claimable><name>Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer</name><description>This research study is studying a drug in combination with radiation therapy as a possible treatment for hepatic metastases from colorectal cancer.
The interventions involved in this study are:
* Trifluridine (TAS-102)
* Radiation Therapy</description><dates><creation>2017-10-15</creation></dates><accession>2249799</accession><cross_references><ClinicalTrials___gov>NCT03223779</ClinicalTrials___gov></cross_references></HashMap>